Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 241

Similar articles for PubMed (Select 22690748)

1.

Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.

Richter JM, Kushkuley S, Barrett JA, Oster G.

Aliment Pharmacol Ther. 2012 Aug;36(3):248-56. doi: 10.1111/j.1365-2036.2012.05175.x. Epub 2012 Jun 12.

PMID:
22690748
2.

Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.

Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T.

Aliment Pharmacol Ther. 2013 Aug;38(3):264-73. doi: 10.1111/apt.12362. Epub 2013 Jun 5.

PMID:
23734840
3.

Ulcerative proctitis: a review of pharmacotherapy and management.

Lakatos PL, Lakatos L.

Expert Opin Pharmacother. 2008 Apr;9(5):741-9. doi: 10.1517/14656566.9.5.741. Review.

PMID:
18345952
4.

Topical therapy is underused in patients with ulcerative colitis.

Seibold F, Fournier N, Beglinger C, Mottet C, Pittet V, Rogler G; Swiss IBD cohort study group.

J Crohns Colitis. 2014 Jan;8(1):56-63. doi: 10.1016/j.crohns.2013.03.005. Epub 2013 Apr 6.

PMID:
23566922
5.

Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.

Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD.

Inflamm Bowel Dis. 2006 Oct;12(10):979-94.

PMID:
17012969
6.
7.

Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD004118. doi: 10.1002/14651858.CD004118.pub2. Review.

PMID:
23152224
8.

Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.

Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, D'Arienzo A, Gaia E, Gullini S, Riegler G, Valentini M, Massa P, Del Piano M, Rossini F, Guidetti CS, Pera A, Greinwald R, Bianchi Porro G.

Ital J Gastroenterol Hepatol. 1999 Nov;31(8):677-84.

PMID:
10730559
9.

Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.

Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola C, Miglioli M, Campieri M.

Dis Colon Rectum. 1998 Jan;41(1):93-7.

PMID:
9510317
10.

Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.

Mantzaris GJ, Hatzis A, Petraki K, Spiliadi C, Triantaphyllou G.

Dis Colon Rectum. 1994 Jan;37(1):58-62.

PMID:
8287749
11.

Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.

Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee AA, Dewit O, Probert CS, Aoucheta D; MOTUS study investigators.

Aliment Pharmacol Ther. 2013 Apr;37(8):767-75. doi: 10.1111/apt.12266. Epub 2013 Mar 4.

PMID:
23451806
12.

A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.

Cohen RD, Woseth DM, Thisted RA, Hanauer SB.

Am J Gastroenterol. 2000 May;95(5):1263-76.

PMID:
10811338
13.

Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis.

Pica R, Paoluzi OA, Iacopini F, Marcheggiano A, Crispino P, Rivera M, Bella A, Consolazio A, Paoluzi P.

Inflamm Bowel Dis. 2004 Nov;10(6):731-6.

PMID:
15626890
14.

Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.

Heyman MB, Kierkus J, Spénard J, Shbaklo H, Giguere M.

Inflamm Bowel Dis. 2010 Nov;16(11):1931-9. doi: 10.1002/ibd.21256.

15.

Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.

Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P.

J Crohns Colitis. 2014 Mar;8(3):200-7. doi: 10.1016/j.crohns.2013.08.007. Epub 2013 Sep 4.

16.
17.

Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial.

Gionchetti P, D'Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A, Varoli G, Campieri M; Italian BDP Study Group.

J Clin Gastroenterol. 2005 Apr;39(4):291-7.

PMID:
15758622
18.

Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.

Andus T, Kocjan A, Müser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, Dorofeyev AE, Lozynskyy YS, Cascorbi I, Stolte M, Vieth M, Dilger K, Mohrbacher R, Greinwald R; International Salofalk Suppository OD Study Group.

Inflamm Bowel Dis. 2010 Nov;16(11):1947-56. doi: 10.1002/ibd.21258.

PMID:
20310020
19.

The role of aminosalicylates in the treatment of ulcerative colitis.

Van Assche G, Baert F, De Reuck M, De Vos M, De Wit O, Hoang P, Louis E, Mana F, Pelckmans P, Rutgeerts P, Van Gossum A, D'Haens G.

Acta Gastroenterol Belg. 2002 Oct-Dec;65(4):196-9.

PMID:
12619425
20.

Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.

Cortot A, Maetz D, Degoutte E, Delette O, Meunier P, Tan G, Cazals JB, Dewit O, Hebuterne X, Beorchia S, Grunberg B, Leprince E, D'Haens G, Forestier S, Idier I, Lémann M.

Am J Gastroenterol. 2008 Dec;103(12):3106-14. doi: 10.1111/j.1572-0241.2008.02152.x.

PMID:
19086960
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk